Ribociclib succinate is under clinical development by Novartis and currently in Phase II for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer). According to GlobalData, Phase II drugs for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer) have a 44% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Ribociclib succinate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Ribociclib succinate overview

Ribociclib succinate (Kisqali, Kryxana) is an antineoplastic agent. It is formulated as film coated tablets for oral route of administration. Ribociclib succinate in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of postmenopausal women with hormone receptor positive and HER2 negative advanced or metastatic breast cancer.

Ribociclib succinate is under development for the treatment of hepatocellular carcinoma, endometrial carcinoma (third line therapy), metastatic castrate resistant prostate cancer, lymphoma, malignant rhabdoid tumors, teratoma, recurrent glioblastome multiforme or glioma, ovarian cancer, recurrent head and neck cancer squamous cell carcinoma, metastatic triple-negative breast cancer, peritoneal cancer, ALK-positive non-small cell lung cancer, neuroblastoma,  advanced or metastatic BRAF V600 mutant melanoma, well differentiated and dedifferentiated liposarcomas, mantle cell lymphomas, head and neck cancers, metastatic adenocarcinoma of the pancreas, diffuse intrinsic pontine glioma, high grade glioma, metastatic KRAS-mutant colorectal cancer, well differentiated neuroendocrine tumors of foregut origin such as thymic carcinoma, bronchopulmonary cancer, gastric cancer, duodenal cancer, relapsed and refractory acute lymphocytic leukemia, medulloblastoma, atypical teratoid rhabdoid tumor, malignant rhabdoid tumor, rhabdomyosarcoma, medulloblastoma, anaplastic astrocytoma, anaplastic oligodendroglioma, anaplastic pleomorphic xanthoastrocytoma. Ribociclib in combination with PDR001 is under development for the treatment of metastatic hormone receptor positive breast cancer and metastatic ovarian cancer. It is under development for the treatment of women with hormone receptor positive and HER2 negative locally advanced or metastatic breast cancer in combination with fulvestrant as in women who have received prior endocrine therapy. It was under development for the treatment of teratoma. It was under development for the treatment of teratoma.

Novartis overview

Novartis is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products. It provides drugs for the treatment of cancer, cardiovascular diseases, dermatological conditions, neurological disorders, ophthalmic and respiratory diseases, hematologic diseases, solid tumors, immune disorders, and infections, among others. The company offers generic medicines and biosimilars through Sandoz. Novartis conducts research in various disease areas through The Novartis Institutes for BioMedical Research (NIBR). The company operates through a network of subsidiaries and offices across the Americas, Europe, the Middle East, Africa, and Asia-Pacific. Novartis is headquartered in Basel, Switzerland.

For a complete picture of Ribociclib succinate’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.